Abstract: A process for the preparation of bromostyrenes which comprises aqueous alcoholic alkali dehydrohalogenation of a 1-haloethyl bromobenzene, a 2-haloethyl bromobenzene, or a 1-methyl-2-haloethyl brominated benzene in the presence of a phase transfer catalyst at a temperature of between about 0.degree. C. and about 150.degree. C. The bromostyrenes have the particular utility as a comonomer for the preparation of a co-polymer exhibiting a flame retardancy. Both bromostyrenes and brominated alpha-methyl styrenes are formed.

Abstract: Described are para-carboalkoxy cyclohexanones defined according to the structure: ##STR1## wherein R.sub.1 represents hydrogen or C.sub.1 -C.sub.7 alkyl and R.sub.2 represents methyl or ethyl and uses thereof in augmenting or enhancing the aroma of consumable materials including foodstuffs, chewing gums, toothpastes, medicinal products, chewing tobaccos, perfume compositions, colognes and perfumed articles (e.g., solid or liquid anionic, cationic, nonionic or zwitterionic detergents, cosmetic compositions, fabric softener compositions, fabric softener articles, hair preparations and perfumed polymers. The compounds defined according to the structure: ##STR2## wherein R.sub.1 ' represents C.sub.4 -C.sub.7 alkyl and R.sub.2 represents methyl or ethyl are novel compounds.

Abstract: A method has been disclosed for treating type 1 or 2 herpes simplex virus comprising the successive steps of:(1) topically applying to the virus-affected areas of a person suffering from said virus, a topically effective amount of an anthaquinone, containing extract having an antiviral effect of type 1 or type 2 herpes simplex virus, and(2) repeating said topical application as required until the desired antiviral effect is observed.

Abstract: A storage-stable sucralfate-containing preparation which maintains its ability, even after extended periods of time, to form a viscous, sticky, paste-like material in the presence of gastric secretions is disclosed as well as the method of making same.

Abstract: This invention relates to a method for combatting viral infections in a mammal comprising administering to the mammal an acylpeptide of the formula ##STR1## wherein R.sup.1 is lactoyl-alanyl, R.sup.2 is carboxymethylamino and R.sup.3 is carboxy; or R.sup.1 is heptanoyl, R.sup.2 is 1-carboxyethylamino and R.sup.3 is carboxy; or R.sup.1 is stearoyl, R.sup.2 is 1-carboxyethylamino and R.sup.3 is hydrogen; or R.sup.1 is octanoyl, R.sup.2 is 1-carboxyethylamino and R.sup.3 is hydrogen.

Abstract: Diuretic and natriuretic extracts, which have been characterized as peptide in nature, have been obtained by homogenization of mammalian heart atria with an aqueous solution of a lower carboxylic acid and may be prepared synthetically. After precipitation of impurities by pH adjustment, the extract may be further purified chromatographically. Extracts injected into test rats resulted in 30-40 fold increases in sodium and chloride excretions within 5-10 minutes of injection. Urine volume rose 10-15 fold and potassium excretion doubled. The response was complete in 20 minutes and no similar changes in renal function were observed following injection of a similarly obtained ventricular extract.

Abstract: Improved methods of anesthesia for mammals, especially humans, are provided wherein the prolonging effect upon local anesthesia which is exhibited by co-administration of vasoconstrictors, especially vasoconstrictors believed to act upon alpha adrenoreceptor sites on blood vessel walls, are provided. In accordance with a preferred embodiment, alpha adrenoreceptor blocking agents are aministered subsequent to the performance of surgery or dentistry under local anesthesia accomplished through co-administration of anesthesia and vasoconstrictor to cause reduction of prolonged anesthetic effect. Seriatim procedures are facilitated under local anesthesia through employment of the present invention. Improved patient aesthetics, diminution of self-inflicted trauma, and increased sensory feedback from patients are among the benefits conferred by the present invention.

Abstract: Two sets of hormonal peptides are synthesized which are super agonists of the lutenizing hormone releasing hormone (LHRH). Chronic administration results in the inhibition of LHRH which is responsible for stimulating cell growth in the testes. One peptide has the D(dextro)-form of a mono-heterocyclic amino acid in position six (D-3-pyridyl-alanine) while the other peptide has a bi-heterocyclic amino acid in that same position (.beta.-(3-quinolyl)-D-.alpha.-alanine. Both peptides are less metabolically reactive than those in the prior art and yet both peptides are significantly more potent than LHRH itself.

Abstract: A process for the preparation of the N-L-.alpha.-aspartyl-L-phenylalanine 1-methyl ester (aspartame) which is characterized by adding phosphoric acid and a lower alkyl alcohol to the reaction mixture containing N-formyl .alpha.-L-aspartyl- and .beta.-L-aspartyl-L-phenyl-alanine methyl ester and only one of the resultant deformylated isomers, i.e. aspartame phosphate precipitates.The .alpha.-isomer phosphate is collected by filtration and converted to free aspartame by treatment with a base.

Abstract: The symptoms of chronic alveolar emphysema in horses are palliated by daily feeding the effected horses a handful of the red berries from the staghorn sumac for a period of at least about two weeks.

Abstract: The present invention relates to animal feed block compositions containing a growth promoter, such as avoparcin, and an organic or mineral acid. The feed blocks of this invention exhibit improved potency retention of the growth promoter. Further provided are methods for enhancing the growth promoter potency retention of such feed blocks by adjusting the pH of the feed blocks below pH 7 with the organic or mineral acid.

Abstract: A solid fibrinogen formulation is described, which formulation contains, in addition to fibrinogen, a substance containing the urea or guanidine radical, and a process for its preparation. This formulation is used for the preparation of a fibrinogen solution which is suitable as an adhesive for human and animal tissue and as a fibrinogen concentrate for intravenous administration.

Abstract: New peptides are disclosed which have biological activity of the same type as known calcitonins and which are amide analogs of natural calcitonins.

Abstract: A treatment for temporary relief of pain wherein a single dose comprises the following: 4 grams calcium gluconate by injection, 1 gram Vitamin C (calcium ascorbate), 100 mg magnesium hydroxide, 50 mg Vitamin B.sub.6 (pyridoxine hydrochloride), 1 gram pantothenic acid, effervescent solution.

Abstract: Beverage product, especially adapted for rapid administration of water and carbohydrates to the human body during periods of heavy muscle work, which consists of a preferably monosaccharide-free solution containing 3-25% by weight of a mixture of soluble oligosaccharides with DP values between 2 and 10 inclusive, the average DP value of the oligosaccharide mixture preferably being in the range 3-5; at least one physiologically acceptable alkalizing compound or compound combination; and optionally salts occuring in body liquids and suitably aroma and taste-improving substances, all of them in minor amounts; the solution's content of the physiologically acceptable alkalizing compound or compound combination being such that when the beverage is consumed during heavy muscle work (e.g. at 60% of the maximal aerobic capacity) in an amount of 250 mls each fifteenth minute during one hour gives an increase of the pH value in the vertricle contents to above 3.5, preferably above 4.5, especially above 7.0.

Abstract: L-2-oxothiazolidine-4-carboxylate, a sulfur analog of 5-oxoproline, is cleaved by the enzyme 5-oxo-L-prolinase to form cysteine, thus providing the basis for a cysteine delivery system by the addition of L-2-oxothiazolidine-4-carboxylate to base amino acid solutions or by injecting it directly into in vivo cells.

Abstract: Physical and emotional symptoms characteristic of withdrawal from narcotics addiction are reduced or eliminated entirely by treatment with a unique combination of naturally-derived ingredients, primarily herbal in origin, the component of highest concentration being Ginseng radix. Other components of the composition include Amanae bulbus, Puchrestrae radix, Euphorbiae pekinensis, Lathyridis semen, Auicular margark feral, Manis squama, Zizyphi spinosi semen, Angelicae gigantis radix, Cnidii rhizoma, Rehmaniae radix and Paeoniae radix. The composition is administered internally, preferably orally, to the subject upon cessation of narcotics intake, with the result that most of the symptoms normally associated with such withdrawal are severely reduced in intensity.

Abstract: Anhydrous dentifrice having desirable rheological, sensory and hygienic characteristics containing a polysaccharide gum and glycerine humectant. Ingredients at least partially incompatible when water is present, such as zeolite or molecular sieve, may be included. The polysaccharide is clarified or non-clarified deacetylated heteropolysaccharide S-60.

Abstract: There is described a mixture of 4-[2-(6-(2-phenylethylamino)hexylamino)ethyl]-1,2-benzenediol, or 4-[2-(6-(2-chlorophenyl)ethylamino)hexylamino)ethyl]-1,2-benzenediol or a pharmaceutically acceptable acid addition salt of either thereof or as active ingredient, and a physiologically acceptable acid.There is also described a method of preparing a solid form of the active ingredient, which comprises freeze drying an aqueous solution of the mixture, and a freeze dried composition containing the active ingredient prepared by the method.The mixtures are useful as pharmaceuticals, e.g. in the treatment of cardiovascular conditions.

Abstract: Atrial peptides useful in practising the invention have the formula: ##STR1## wherein R.sub.1 is Arg, Leu-Arg, Ser-Leu-Arg, Arg-Ser-Leu-Arg, Pro-Arg-Ser-Leu-Arg, Gly-Pro-Arg-Ser-Leu-Arg, Ala-Gly-Pro-Arg-Ser-Leu-Arg or Leu-Ala-Gly-Pro-Arg-Ser-Leu-Arg; R.sub.17 is Met or Ile, R.sub.31 is Phe or desR.sub.31 ; R.sub.32 is Arg or desR.sub.32 ; R.sub.33 is Tyr or desR.sub.33 ; and Y is OH or NH.sub.2. These peptides or pharmaceutically acceptable salts thereof, dispersed in a pharmaceutically acceptable liquid or solid carrier, can be administered to mammals, particularly humans, in order to inhibit basal aldosterone secretion and/or to manage aldosterone-dependent hypertention.